Life Sciences

  • June 16, 2026

    Eli Lilly Settles Mounjaro TM Suit Against Seattle Area Clinics

    Eli Lilly has agreed to drop a lawsuit accusing two Washington clinics of ripping off its trademarks for the weight loss drugs Mounjaro and Zepbound, according to a voluntary dismissal motion filed in federal court on Monday, almost two weeks after a judge rejected a resolution proposed by the parties. 

  • June 16, 2026

    Del. Judge Won't Touch Jury's $83M Diagnostics IP Verdict

    A Delaware federal judge on Tuesday upheld a jury's 2023 verdict finding that Guardant Health Inc. should pay TwinStrand Biosciences Inc. $83.4 million for willfully infringing diagnostic patents, refusing to overturn or enhance the award.

  • June 16, 2026

    SEC Settles Insider Trading Suit Against Biotech Investor

    The U.S. Securities and Exchange Commission announced on Tuesday that a Texas-based investor will pay over $240,000 to settle the agency's claims he improperly traded stocks on insider information by buying shares of a public biotech firm ahead of its 2020 merger with a privately held biotechnology company.

  • June 16, 2026

    Cigna Loses Privilege Bid Due To 'Inaccurate, Redundant' Log

    Cigna "improperly asserted privilege" over hundreds of documents that three laboratories sought as part of the discovery process in federal payment litigation in Connecticut, according to a special master appointed by the judge in the consolidated cases.

  • June 16, 2026

    Judge Allows Pfizer, Moderna Defenses In GSK Vax IP Dispute

    A Delaware federal judge on Tuesday permitted Pfizer and Moderna to move ahead with their arguments that GlaxoSmithKline patents the company claims are infringed by the COVID-19 vaccines are unenforceable because of an unreasonable delay in obtaining them.

  • June 16, 2026

    J&J Talc Trial In LA Ends With Deadlocked Jury

    A mistrial was declared Monday by a Los Angeles state judge in a two-month trial over allegations Johnson & Johnson's talc products caused a woman's deadly mesothelioma after the jury deadlocked during deliberations, according to counsel for the plaintiff.

  • June 16, 2026

    Md. Judge Continues Health Case Law Streak With ACA Ruling

    U.S. District Judge Brendan Abell Hurson in Baltimore has been on the bench for less than three years. He's already building an impressive list of healthcare rulings.

  • June 16, 2026

    Pfizer Agrees To Deal To End Depo-Provera MDL

    The plaintiffs in the multidistrict litigation accusing Pfizer of failing to warn consumers of a link between brain tumors and the hormonal contraceptive Depo-Provera have reached an agreement with the pharmaceutical giant, according to an order filed Monday.

  • June 15, 2026

    DOJ Says NY Court Can't Block Texas Trans Records Probe

    The U.S. Department of Justice urged a New York federal court Monday to deny a request for an order barring the government from seeking transgender minor patients' medical records through a criminal subpoena issued by a Texas grand jury, arguing the court lacks jurisdiction.

  • June 15, 2026

    Squires Rejects 7 AIA Cases, Explains Earlier Tesla Decision

    U.S. Patent and Trademark Office Director John Squires has granted five patent challenges and rejected seven others, and he also issued a decision Monday explaining why he allowed a group of Tesla petitions to go ahead to the merits stage of review.

  • June 15, 2026

    Univ. Of Washington Beats Medical Prof's Bias Suit At Trial

    Jurors have cleared the University of Washington's medical school of liability in an anesthesiology professor's lawsuit alleging that she was unfairly ousted from a director role after complaining of discrimination and harassment, finding that the professor failed to sufficiently prove any of her three claims against the school.

  • June 15, 2026

    FTC Pulls OptumRx Insulin Price Case To Review Final Deal

    The Federal Trade Commission's third and final settlement resolving an in-house case accusing pharmacy benefit managers of inflating insulin prices through rebate schemes is in sight after the agency on Friday pulled from adjudication its allegations against UnitedHealth Group Inc.'s OptumRx to review a deal struck with staffers.

  • June 15, 2026

    $239M LabCorp Deal Illegally Shared Genetic Info, Suit Says

    Genetic testing company Invitae Corp. has been hit with proposed class privacy claims by an Illinois parent who says the company unlawfully disclosed its patients' genetic information to LabCorp after the laboratory testing giant bought Invitae out of bankruptcy.

  • June 15, 2026

    CareFirst Says Intent Standard Was Misread In Stelara Case

    CareFirst is arguing that a Virginia federal judge created a new standard for monopolization claims when he dismissed claims from the company's antitrust suit challenging Johnson & Johnson's protection of its immunosuppressive drug Stelara, arguing he misread a Fourth Circuit decision in ruling that monopolization requires a showing of specific intent.

  • June 15, 2026

    Mead Johnson Wins New Trial Over $60M NEC Formula Verdict

    An Illinois appellate panel has thrown out a $60 million jury verdict awarded to a mother claiming Mead Johnson's infant formula caused her premature baby to develop a fatal gut disease, saying the trial court erred in finding the company owed a duty to warn the mother and not just the infant's doctors, and allowing prejudicial evidence about Mead Johnson's profits.

  • June 15, 2026

    Wyo. Judge Nixes 3 Abortion Care Limits As Unconstitutional

    A Wyoming judge has struck down three state laws restricting abortion care, finding that the state failed to demonstrate it had a compelling interest in effectuating a 48-hour waiting period for abortions and requiring certain abortion facilities to be licensed as ambulatory surgical centers, among other restrictions.

  • June 15, 2026

    Nano-X Investors Sue Over Korea Plant Restructuring Hit

    Medical imaging company Nano-X Imaging Ltd. faces a proposed investor class action alleging it failed to tell investors that it had expanded its manufacturing operations beyond what customer demand justified, ultimately leading to a $17.5 million write-down.

  • June 15, 2026

    Hagens Berman Must Cover Fees After Misconduct Findings

    Hagens Berman Sobol Shapiro LLP must cover the fees and costs of a special master who alleged the firm committed misconduct in product liability litigation over the morning sickness drug thalidomide, a Pennsylvania federal judge has said.

  • June 15, 2026

    Mylan Investor Claims Atty Fees Too Much For 'Lost' Case

    An attorney and stockholder in the former Mylan NV objected to the attorneys' fees in a proposed $60 million class action settlement, telling a Pennsylvania federal judge Monday that the plaintiffs' lawyers effectively "lost" a suit that began with allegations of $5.1 billion in lost share value.

  • June 15, 2026

    Judge Gives First OK To $69M ChemoCentryx Deal

    A California federal judge has given the first green light to a $69 million settlement reached between investors and ChemoCentryx, resolving claims that the California-based pharmaceutical company overstated the efficacy of its newly developed treatment for autoimmune disease ANCA vasculitis.

  • June 12, 2026

    Jury Tells Amgen To Pay $20.2M In Antibody Patent Trial

    A Delaware federal jury decided Friday that Amgen Inc. and its Teneobio Inc. unit willfully infringed a mouse antibody patent asserted by Harbour Antibodies BV and others, and should pay $20.2 million in damages — the full amount Harbour was seeking.

  • June 12, 2026

    J&J Trial Over Doctor's Cancer Death Ends In Settlement

    A long-running dispute over whether Johnson & Johnson's baby powder caused the cancer that killed a Miami anesthesiologist concluded with a settlement just before closing arguments in a second trial after the first ended in a hung jury. 

  • June 12, 2026

    Disability Rights Orgs. Seek To Halt NY, Ill. 'Aid-In-Dying' Laws

    Disability rights organizations hit the governors of New York and Illinois with a pair of federal lawsuits seeking to stop new laws in each state from taking effect that would allow patients with terminal illnesses to seek a doctor's assistance in ending their lives.

  • June 12, 2026

    Zoetis Brass Face Derivative Suit Over Pet Meds Statements

    Directors and officers of animal health company Zoetis Inc. have been hit with shareholder derivative claims that they breached their fiduciary duties by concealing that safety warnings about one of its products and increasing competition were hurting the company's bottom line.

  • June 12, 2026

    Insider Trading Defense May Draw On 'Varsity Blues' Playbook

    After enlisting a crew of experienced attorneys, defendants charged in an insider trading case allegedly involving deal information stolen from huge law firms are preparing to use a strategy that could take some cues from the "Varsity Blues" case in the same Boston courthouse.

Expert Analysis

  • Series

    Watching Hallmark Movies Makes Me A Better Lawyer

    Author Photo

    I realize you may be judging me for watching, and actually enjoying, Hallmark Channel movies, but the escapism and storylines actually demonstrate qualities and actions that lead to an efficient, productive and positive legal practice, says Karen Ross at Tucker Ellis.

  • New Orphan Drug Law Provides A Key Fix For Pharma Cos.

    Author Photo

    The Consolidated Appropriations Act enacted last month restores the U.S. Food and Drug Administration's long-standing interpretation of "same disease or condition," related to orphan drug exclusivity, resolving years of regulatory uncertainty and litigation that have discouraged rare disease research, say attorneys at Spencer Fane.

  • When Trade Secret Litigation And Criminal Law Collide

    Author Photo

    An increasing convergence of trade secret litigation and white collar defense, especially with several recent criminal prosecutions from the Justice Department, should prompt businesses and counsel to adapt within the overlapping landscapes, says Kenneth Notter at MoloLamken.

  • Opinion

    PTAB Needs Reform To Protect Inventors From Larger Cos.

    Author Photo

    The Promoting and Respecting Economically Vital American Innovation Leadership Act is necessary because it will impose additional requirements on patent validity challenges and prevent large corporations from taking advantage of the Patent Trial and Appeal Board to overwhelm small inventors with repeated litigation, says Eb Bright at ExploraMed Development.

  • FDA User Fee Talks Offer Clues On Upcoming Reforms

    Author Photo

    As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.

  • Moderna Case Highlights Overlooked Hurdle In Biopharma IP

    Author Photo

    The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.

  • FDA Framework For Personalized Therapies Raises Questions

    Author Photo

    The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.

  • Emissions Permits May Not Override Pollution Exclusions

    Author Photo

    Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

  • CMS Healthcare Enforcement Initiatives May Cause Disruption

    Author Photo

    The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.